Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AtriCure, Inc.ATRC · Entity 2704 | Chief Mktg & Strategy Officer | July 29, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AtriCure, Inc.
Report date July 29, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,219 |
Reported balance
After 2026-07-29 transaction · row 1
1 source rowRow 1 · 2026-07-29 · Sale · Disposed 6,182 · Balance 100,219 F1: This transaction was executed in multiple trades at prices ranging from $38.62 to $39.28 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $38.62 to $39.28 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 30, 2026 20:57 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 6,182 | $38.80 | $239,861.60 |
DisclosureSEC source: 0001666600-26-000004 · wk-form4_1785445064.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,219 F1 · price: This transaction was executed in multiple trades at prices ranging from $38.62 to $39.28 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:53 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 15,586 | $31.26 | $487,218.36 |
DisclosureSEC source: 0001666600-26-000002 · wk-form4_1772574787.xml · nonDerivative · entry 3 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,401 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:53 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 15,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001666600-26-000002 · wk-form4_1772574787.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,987 F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:53 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 27,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001666600-26-000002 · wk-form4_1772574787.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,789 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| November 26, 2025 Filed Nov 26, 2025 21:41 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 5,166 | $37.29 | $192,640.14 |
DisclosureSEC source: 0001666600-25-000005 · wk-form4_1764193301.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,798 F1 · price: This transaction was executed in multiple trades at prices ranging from $36.51 to $38.44 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 12:45 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 3,000 | $36.30 | $108,900.00 |
DisclosureSEC source: 0001666600-25-000003 · wk-form4_1758026753.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,964 F1 · price: This transaction was executed in multiple trades at prices ranging from $36.28 to $36.36 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:00 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 9,673 | $38.74 | $374,732.02 |
DisclosureSEC source: 0001323885-25-000022 · wk-form4_1741125634.xml · nonDerivative · entry 3 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,964 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:00 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 6,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-25-000022 · wk-form4_1741125634.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,637 F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:00 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 19,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-25-000022 · wk-form4_1741125634.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,058 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 13:48 UTC | AtriCure, Inc. ATRC · Entity 2704 | GiftCommon Stock | 585 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-24-000119 · wk-form4_1734011301.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,699 F1 · price: No consideration was received in connection with this charitable gift. Read SEC document |
| May 01, 2024 Filed May 3, 2024 12:51 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 1,500 | $24.09 | $36,135.00 |
DisclosureSEC source: 0001323885-24-000064 · wk-form4_1714740653.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,284 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan adopted on December 12, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 12:41 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 1,500 | $30.39 | $45,585.00 |
DisclosureSEC source: 0001323885-24-000053 · wk-form4_1712148053.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,784 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan adopted on December 12, 2023. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 12:55 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 1,500 | $36.72 | $55,080.00 |
DisclosureSEC source: 0001323885-24-000042 · wk-form4_1710420943.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,284 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan adopted on December 12, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:44 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 8,856 | $36.28 | $321,295.68 |
DisclosureSEC source: 0001323885-24-000032 · wk-form4_1709675029.xml · nonDerivative · entry 3 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,784 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:44 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 9,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-24-000032 · wk-form4_1709675029.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,640 F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:44 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 19,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-24-000032 · wk-form4_1709675029.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,312 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 12:18 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 547 | $38.11 | $20,846.17 |
DisclosureSEC source: 0001323885-23-000083 · wk-form4_1688386678.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,018 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2023. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023, which is the first trading day of the applicable offering period. The closing price on January 3, 2023 was $44.84. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:14 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 7,083 | $38.81 | $274,891.23 |
DisclosureSEC source: 0001323885-23-000028 · wf-form4_167788158601727.xml · nonDerivative · entry 3 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,471 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:14 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 16,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-23-000028 · wf-form4_167788158601727.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,554 F2 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:14 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 8,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-23-000028 · wf-form4_167788158601727.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,450 F1 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The award had both a Company performance goal and a service period requirement, which were both met. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 22:12 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 585 | $34.86 | $20,393.10 |
DisclosureSEC source: 0001323885-23-000004 · wf-form4_167278391044535.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,414 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended December 31, 2022. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 1, 2022, which is the first trading day of the applicable offering period. The closing price on July 1, 2022 was $41.01. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:33 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 7,474 | $69.59 | $520,115.66 |
DisclosureSEC source: 0001323885-22-000029 · wf-form4_164634319843566.xml · nonDerivative · entry 3 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,829 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:33 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 6,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-22-000029 · wf-form4_164634319843566.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,303 F2 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:33 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 7,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-22-000029 · wf-form4_164634319843566.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,478 F1 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The award had both a Company performance goal and a service period requirement, which were both met. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 12:10 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 4,119 | $80.00 | $329,520.00 |
DisclosureSEC source: 0001209191-21-043590 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,689 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 12:54 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-21-042665 · doc4.xml · derivative · entry 4 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 12:54 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 6,000 | $76.36 | $458,160.00 |
DisclosureSEC source: 0001209191-21-042665 · doc4.xml · nonDerivative · entry 3 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,808 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $74.11 to $77.13 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 12:54 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 15,000 | $76.36 | $1,145,400.00 |
DisclosureSEC source: 0001209191-21-042665 · doc4.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,808 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $74.11 to $77.13 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 12:54 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 15,000 | $18.30 | $274,500.00 |
DisclosureSEC source: 0001209191-21-042665 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| May 05, 2021 Filed May 6, 2021 12:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | GiftCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030536 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,808 F1 · price: No consideration was received in connection with this gift to charity. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 13,840 | $66.31 | $917,730.40 |
DisclosureSEC source: 0001209191-21-017240 · doc4.xml · nonDerivative · entry 3 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,108 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 6,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017240 · doc4.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,948 F2 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 7,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017240 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,539 F1 · price: The Reporting person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Equity Incentive Plan. The award had both a Company performance goal and a service period requirement, which were both met. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 12:45 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-21-001759 · doc4.xml · derivative · entry 4 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F5 · derivative.exercise_date: These options were granted on January 6, 2014. The options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 12:45 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 8,397 | $53.61 | $450,163.17 |
DisclosureSEC source: 0001209191-21-001759 · doc4.xml · nonDerivative · entry 3 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,608 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $52.83 to $55.65 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 12:45 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 15,000 | $53.57 | $803,550.00 |
DisclosureSEC source: 0001209191-21-001759 · doc4.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,005 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $52.67 to $55.65 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 12:45 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 15,000 | $18.30 | $274,500.00 |
DisclosureSEC source: 0001209191-21-001759 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 12:53 UTC | AtriCure, Inc. ATRC · Entity 2704 | GiftCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-057822 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,005 F1 · price: No consideration was received in connection with this gift to charity. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 12:01 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0001209191-20-025032 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,255 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F2 · balance_after: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.03 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 12:05 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 10,000 | $35.00 | $350,000.00 |
DisclosureSEC source: 0001209191-20-023993 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,255 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:17 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 14,638 | $38.42 | $562,391.96 |
DisclosureSEC source: 0001209191-20-015136 · doc4.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,255 F2 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:17 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 8,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015136 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,893 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 12:34 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-20-001471 · doc4.xml · derivative · entry 4 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 15,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 12:34 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 14,134 | $32.89 | $464,867.26 |
DisclosureSEC source: 0001209191-20-001471 · doc4.xml · nonDerivative · entry 3 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,434 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $32.57 to $33.00 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 12:34 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 15,000 | $32.89 | $493,350.00 |
DisclosureSEC source: 0001209191-20-001471 · doc4.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,568 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $32.60 to $33.00 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 12:34 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 15,000 | $18.30 | $274,500.00 |
DisclosureSEC source: 0001209191-20-001471 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 11:46 UTC | AtriCure, Inc. ATRC · Entity 2704 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-046245 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,568 F1 · price: No consideration was received in connection with this gift to charity. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 11:03 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001209191-19-037902 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,068 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| April 30, 2019 Filed May 2, 2019 11:02 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-19-026889 · doc4.xml · derivative · entry 3 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F4 · derivative.exercise_date: These options were granted on January 6, 2014 and are exercisable as to 25% of the shares one year from the date of grant, and the remaining 75% thereafter vests and is exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| April 30, 2019 Filed May 2, 2019 11:02 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 15,000 | $30.00 | $450,000.00 |
DisclosureSEC source: 0001209191-19-026889 · doc4.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,068 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.04 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.